The estimated Net Worth of Jeffrey H Barnes is at least $451 mil dollars as of 5 August 2010. Jeffrey Barnes owns over 65,488 units of Icad Inc stock worth over $252,111 and over the last 18 years Jeffrey sold ICAD stock worth over $198,585.
Jeffrey has made over 3 trades of the Icad Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Jeffrey sold 65,488 units of ICAD stock worth $136,215 on 5 August 2010.
The largest trade Jeffrey's ever made was selling 65,488 units of Icad Inc stock on 5 August 2010 worth over $136,215. On average, Jeffrey trades about 8,260 units every 43 days since 2006. As of 5 August 2010 Jeffrey still owns at least 181,375 units of Icad Inc stock.
You can see the complete history of Jeffrey Barnes stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is C/O ICAD INC., 4 TOWNSEND WEST, SUITE 17, NASHUA, NH, 03063.
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton y Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: